
Valitse etikettisi
näkyy suoraan injektiopullossaLaboratorioraportti
PDF- Testattu
- Orforglipron 6mg × 100 Tabs
- Laboratorio
- Analiza Białek
- Päivämäärä
- October 2026
- Tulos
- 5.91 mg per tablet (6 mg label)
- Tilauksen nro
- Salasana
Testattu riippumattomasti, tarkistettavissa salasanalla suoraan laboratoriossa.
Orforglipron
GLP-1 Oral
- Laboratoriotestattu
- Lähetetään Saksasta
Tilaus
- DHL seurannalla
- Huomaamaton pakkaus
Yhdellä silmäyksellä
Orforglipron lukuina
Tietopankkimme keskeiset luvut.
Koko tietopankkiartikkeli- Class
- GLP-1 agonistsmall molecule, oral
- Half-life
- longdosed daily
- Use
- Oralin mg/day
- Sizes
- 3 sizes6mg/90tabs, 6mg/100tabs, 12mg/100tabs
Arvostelut
Mitä asiakkaat sanovat
Vain todelliset tilaukset, joissa oli Orforglipron.
Kaikki arvostelutTietoa
Kaikki aiheesta Orforglipron
Tarkemmat tiedot tulossa pian.
How does Orforglipron differ from semaglutide as a tablet?
Semaglutide is a peptide and is poorly absorbed in the stomach, which is why a strict fasting rule applies. Orforglipron is a small molecule that acts on the same GLP-1 receptor. With food the absorbed amount was only about 18 to 24 percent lower in two studies, half-life and time to peak stayed the same. The US prescribing information states no clinically relevant food effect.
Is Orforglipron approved?
Yes, in the US since 1 April 2026 for long-term weight reduction in adults with obesity or with overweight and at least one related condition. Applications were under review in the EU, Japan and Canada in 2026, also for type 2 diabetes. The approved tablets have different strengths than the capsules used in the trials, so the numbers are not directly comparable.
How much did weight drop in the trials?
In the phase 3 trial with 3,127 adults without diabetes weight fell by 7.5, 8.4 and 11.2 percent over 72 weeks depending on the level, by 2.1 percent on placebo. In the highest level 54.6 percent lost at least a tenth of their weight and 18.4 percent at least a fifth. With type 2 diabetes the loss was 5.1 to 9.6 percent. Waist size, systolic blood pressure and blood lipids improved.
How does it perform in type 2 diabetes?
In early type 2 diabetes HbA1c fell by 1.24 to 1.48 percentage points over 40 weeks, by 0.41 on placebo. There were no severe hypoglycaemias. In a 52-week head-to-head trial both tested Orforglipron levels lowered HbA1c more than both levels of oral semaglutide, 1.91 against 1.47 percentage points comparing the higher levels.
Which side effects were seen?
Mainly gastrointestinal complaints such as nausea, constipation, diarrhoea and vomiting, mostly mild to moderate and mainly during dose escalation. Compared with oral semaglutide 58 to 59 percent had such complaints against 37 to 45 percent. 9 to 10 percent stopped against 4 to 5 percent. Pulse rose by up to 4.7 beats per minute on average.
Why is one tablet a day enough?
Orforglipron stays in the blood for a long time. In the first human study the half-life after several weeks was 48 to 68 hours, the US prescribing information gives 29 to 49 hours. A steady level is reached after about a week. It is broken down mainly in the liver via CYP3A4, so interactions with drugs that slow down or speed up this enzyme matter.
Does it help to keep weight off after injection therapy?
One trial tested this: people who switched to Orforglipron after 72 weeks of injected tirzepatide or semaglutide kept on average 74.7 and 79.3 percent of their previous loss after one year, 49.2 and 37.6 percent on placebo. There was no arm that continued the injection and the trial ran for one year only.
Liittyvät
Samankaltaiset tuotteet
Orforglipron